The purpose of this paper is to provide the rationale for therapeutic silencing of the alpha-synuclein gene (SNCA) in Parkinson’s disease (PD). The paper reviews the public health significance of PD; the causal links between rare SNCA variants and familial PD; the association of common SNCA variants and PD susceptibility; the association of SNCA variants also with age at onset and motor and cognitive outcomes in PD; therapeutic strategies targeting SNCA in PD; and preliminary findings and considerations on small interfering RNA-based therapies and PD.

Citations

Citations to this article as recorded by  

• Antisense therapies in neurological diseases
  Jean-Baptiste Brunet de Courssou, Alexandra Durr, David Adams, Jean-Christophe Corvol, Louise-Laure Mariani
  Brain.2022; 145(3): 816.     CrossRef
• Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
  L. Ma, M. Gholam Azad, M. Dharmasivam, V. Richardson, R.J. Quinn, Y. Feng, D.L. Pountney, K.F. Tonissen, G.D. Mellick, I. Yanatori, D.R. Richardson
  Redox Biology.2021; 41: 101896.     CrossRef
• Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA
  Peiyuan Zhang, Hye-Jin Park, Jie Zhang, Eunsung Junn, Ryan J. Andrews, Sai Pradeep Velagapudi, Daniel Abegg, Kamalakannan Vishnu, Matthew G. Costales, Jessica L. Childs-Disney, Alexander Adibekian, Walter N. Moss, M. Maral Mouradian, Matthew D. Disney
  Proceedings of the National Academy of Sciences.2020; 117(3): 1457.     CrossRef
• Small molecule recognition of disease-relevant RNA structures
  Samantha M. Meyer, Christopher C. Williams, Yoshihiro Akahori, Toru Tanaka, Haruo Aikawa, Yuquan Tong, Jessica L. Childs-Disney, Matthew D. Disney
  Chemical Society Reviews.2020; 49(19): 7167.     CrossRef
• Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease
  Yun Joong Kim, Junbeom Jeon, Jaemoon Shin, Nan Young Kim, Jeong Hoon Hong, Jae-Min Oh, SangKyoon Hong, Yeo Jin Kim, Young-Eun Kim, Suk Yun Kang, Hyeo-Il Ma, Unjoo Lee, Jeehee Yoon
  Movement Disorders.2017; 32(8): 1211.     CrossRef
• Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy
  Michele Schlich, Francesca Longhena, Gaia Faustini, Caitriona M. O’Driscoll, Chiara Sinico, Anna Maria Fadda, Arianna Bellucci, Francesco Lai
  Nano Research.2017; 10(10): 3496.     CrossRef
• Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
  Elvira Valera, Brian Spencer, Eliezer Masliah
  Neurotherapeutics.2016; 13(1): 179.     CrossRef
• Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders
  Hayate Javed, Sindhu A Menon, Karima M Al-Mansoori, Abdelmojib Al-Wandi, Nour K Majbour, Mustafa T Ardah, Shiji Varghese, Nishant N Vaikath, M Emdadul Haque, Mimoun Azzouz, Omar MA El-Agnaf
  Molecular Therapy.2016; 24(4): 746.     CrossRef